Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17637585 | 0.98 | TDP1 (0.59) | TDP1ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL17084551 | 0.95 | TDP1 (0.67) | TDP1ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL16594584 | 0.93 | TDP1 (0.61) | TDP1ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL17084550 | 0.93 | TDP1 (0.53) | TDP1ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL129136 | 0.93 | TDP1 (0.53) | TDP1ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL4201315 | 0.93 | TDP1 (0.53) | TDP1ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL30426434 | 0.91 | TDP1 (0.51) | TDP1ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL17763252 | 0.91 | ALDH1A1 (0.55) | TDP1ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL16594851 | 0.90 | TDP1 (0.61) | TDP1ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL21184519 | 0.90 | TDP1 (0.61) | TDP1ALDH1A1MAPK1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20160296600-A1 | Relaxin Prodrugs | ASCENDIS PHARMA RELAXIN DIVISION A/S (DK) | 2016-10-13 | — | — | US | disclosed |
| US-20160296600-A1 | Relaxin Prodrugs | ASCENDIS PHARMA RELAXIN DIVISION A/S (DK) | 2016-10-13 | — | — | US | disclosed |
| US-9457066-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9457066-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | ASCENDIS PHARMA A/S (DK) | 2016-03-24 | — | — | US | disclosed |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | ASCENDIS PHARMA A/S (DK) | 2016-03-24 | — | — | US | disclosed |
| US-9278139-B2 | Sterilization of biodegradable hydrogels | ASCENDIS PHARMA A/S (DK) | 2016-03-08 | — | — | US | disclosed |
| US-9173953-B2 | Prodrugs containing an aromatic amine connected by an amido bond to a linker | ASCENDIS PHARMA AS (DK) | 2015-11-03 | — | — | US | disclosed |
| US-9173953-B2 | Prodrugs containing an aromatic amine connected by an amido bond to a linker | ASCENDIS PHARMA AS (DK) | 2015-11-03 | — | — | US | disclosed |
| US-8986609-B2 | Sterilization of biodegradable hydrogels | ASCENDIS PHARMA A/S (DK) | 2015-03-24 | — | — | US | disclosed |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2015-01-08 | — | — | US | disclosed |
| US-20120253071-A1 | Sterilization of biodegradable hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | DAO, DNPEP, DDC | TDP1 1488/4885ALDH1A1 899/4885MAPK1 2078/4885 |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | TDP1 2465/4885ALDH1A1 239/4885MAPK1 3294/4885 |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | TDP1 232/4885ALDH1A1 1053/4885MAPK1 2479/4885 |
| US-20160296600-A1 | Relaxin Prodrugs | RXFP1, RXFP2, RXFP3 | TDP1 1781/4885ALDH1A1 3629/4885MAPK1 3848/4885 |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | IAPP, IGF1R, INSR | TDP1 3259/4885ALDH1A1 468/4885MAPK1 118/4885 |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | IAPP, INSR, GPR119 | TDP1 4721/4885ALDH1A1 4742/4885MAPK1 2986/4885 |
| US-20120253071-A1 | Sterilization of biodegradable hydrogels | USP3, USP30, USP4 | TDP1 2333/4885ALDH1A1 664/4885MAPK1 3187/4885 |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | PRAP1, LPXN, DNPEP | TDP1 1450/4885ALDH1A1 2952/4885MAPK1 1207/4885 |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | PTMS, PGLS, PAM | TDP1 696/4885ALDH1A1 193/4885MAPK1 3635/4885 |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | TDP1 2465/4885ALDH1A1 239/4885MAPK1 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.